The need for microdissectional tumor cell preparation during the molecular genetic analysis of prostate cancer

World Journal of Urology

Volumn 17, Issue 2, 1999, Pages 115-122

  Kuczyk, Markus ^a,c   Serth, Jürgen ^a   Bokemeyer, Garsten ^b   Machtens, Stefan ^a   Schwede, Jörn ^a   Herrmann, Roland ^a   Paeslack, Ute ^a   Truss, Michael C ^a   Knüchel, Ruth ^a   Jonas, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ARTICLE; GENETICS; HUMAN; MALE; MUTAGENESIS; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; HUMANS; MALE; MUTAGENESIS; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033110184     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450050116     Document Type: Article

References (34)

1. Ackerman DA. Barry JM, Wicklund RA, Olson N, Löwe BA (1993) Analysis of high risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 150: 1845-1850
2. Adolfsson J. Carstensen T, Lowhagen T (1992) Deferred treatment in localised prostate cancer. Br J Urol 69: 183-187
3. Apakama I, Robinson MC. Walter NM. Charlton RG, Royds JA. Fuller CE. Neal D. Hamdy FC (1996) Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 74: 12581262
4. Bauer JJ, Sesterhenn IA, Mostofi FK. McLeod DG, Srivastava S. Moul JW (1996) Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancers. J Urol 155: 964A
5. Bauer JJ. Connelly RR. Sesterhenn IA. Bettencourt M-C, McLeod DG. Srivastava S, Moul JW (1997) Biostatistical modelling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 79: 952-962
6. Bookstein R. MacGrogan D, Hilsenbeck SG, Sharkley F, Allred DC (1993) P53 is mutated in a subset of advanced stage prostage cancers. Cancer Res 53: 3369-3373
7. Brooks JD. Bova GS. Ewing CM, Carter BS, Robinson J, Piantadosi S. Isaacs WB (1996) P53 alterations do not predict recurrence in primary human prostate cancers. J Urol 155: 966A
8. Castagnaro M. Yandell DW. Dockhorn-Dworniczak B. Wolfe HJ. Poremba C (1993) Androgenrezeptor-Gen Mutationen und p53-Gen Analyse in fortgeschrittenen Prostatakarzinomen. Verh Dtsch Ges Pathol 77: 119-123
9. Dinjens WN, Van der Weiden NM, Schroeder FH, Bosman FT, Trapman J (1994) Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56: 630-633
10. Dong J-T, Isaacs WB, Isaacs JT (1997) Molecular advances in prostate cancer. Curr Opin Oncol 9: 101-107
11. El-Deiry WS, Tokino T, Velgulescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a protein mediator of p53 tumor suppression. Cell 75: 817-825
12. George NJR (1998) Natural history of localised prostate cancer managed by conservative therapy alone. Lancet I: 494-497
13. Goelz SE. Hamilton SR. Vogelstein B (1985) Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 130: 118-126
14. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV. Forman JD, Mesic J, Fu KK, Abrams RA. Pajak TF. Shipley WU. Cox JD (1997) P53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 89: 158-165
15. Harper JW. Adami GR, Wei N. Keyomarski K, Elledge SJ (1993) The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell 75: 805-816
16. Isaacs WB, Carter BS. Ewing CM (1997) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720
17. Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L, Krusemo ÜB (1992) High 10 year survival rate in patients with early untreated prostate cancer. JAMA 267: 2191-2196
18. Kuczyk MA. Serth J, Bokemeyer C. Jonassen J. Arndt H, Paeslack U, Werner M, Tan H-K, Jonas U (1995) Detection of p53 gene alterations in renal cell cancer by micropreparation techniques of tumor specimens. Int J Cancer 64: 399-406
19. Kuczyk MA. Serth J, Machtens S, Bathke W. Minssen A. Jonas U (1997) P53 oncoprotein overexpression predicts local recurrence and long-term survival following radical prostatectomy. J Urol 157: 444A
20. Mellon K. Thompson S, Charlton RG, Marsh C. Robinson M, Lane DP, Harris AL. Home CH, Neal DE (1992) P53. c-erbB2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496-499
21. Mirchandani D, Zheng J, Miller GJ. Gliosh AK, Shibata DK, Cote RJ. Roy-Burman P (1995) Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 147: 92-101
22. Moyret-Lallet C. Marcais C, Jaquemier J, Moles JP. Daver A. Soret JY, Jeameur P. Ozturk M, Theillet C (1995) Ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 64: 124-129
23. Parker SI. Tong T. Beiden S, Wingo PA (1996) Cancer statistics 1996. CA 46: 5-27
24. Stamey TA. Freiha FS, McNeal JE, Redwine EA, Whitemore AS. Schmid HP (1993) Localized prostate cancer: relationship of tumor volume to clinical significance for the treatment of prostate cancer. Cancer 71: 933-938
25. Stapleton AMF, Timme TL, Gouse AE, Li Q-F, Tobon AA, Rattan MW. Slawin KM, Wheeler TM. Scardino PT, Thompson TC (1997) Primary human prostate cancer cells harboring p53 mutations are clonally expanded in métastases Clin Cancer Res 3: 1389-1397
26. Theodorescu D, Broder SR, Boyd JC. Mills SE, Frierson HF (1997) P53, bel-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158: 131-137
27. Thomas DJ. Robinson M. King P, Hasan T. Charlton R, Martin J, Carr TW. Neal DE (1993) P53 expression and clinical outcome in prostate cancer. Br J Urol 72: 778-781
28. Thompson TC. Park SH, Timme TL. Ren C. Eestham JA, Donehower LA, Bradley A, Kadmon D. Yang G (1995) Loss of p53 function leads to metastasis in ras " myc-initiated mouse prostate cancer. Oncogene 10: 869-879
29. Villers A, McNeal JE, Freiha FS, Stamey TA (1992) Multiple cancers in the prostate. Morphologie features of clinically recognized versus incidental tumors. Cancer 70: 2313 2318
30. Visakorpi T, Kallioniemi OP. Heikkinen A. Koivula T. Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887
31. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP (1994) P53 oncogene mutations in human prostate cancer specimens. J Urol 151:492-495
32. Wertz IE, Deitch AD, Gumerlock PH, Gandouredwards R. Chi SG, White R (1996) Correlation of genetic and immuno-detection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 27: 573 580
33. Yang G, Stapleton AMF. Wheeler TM. Truong LD, Timme TL, Scardino PT. Thompson TC (1996) Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. J Urol 155: 965A
34. Zhuang Z. Bertheau P, Emmert-Buck MR, Liotta LA. Gnarra J, Linehan WM, Lubensky IA (1995) A microdissection technique for archival DNA analysis of specific cell populations in lesions < I mm in size. Am J Pathol 146: 620-630